Bicara Therapeutics (BCAX) stock plummeted on Friday after the clinical-stage pharmaceutical company released new trial data. The data comes from its Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab as a treatment for patients with head and neck cancers.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Bicara Therapeutics provided interim results from the study, including a 64% response rate, a median progression-free survival of 9.8 months, and a 12-month overall survival rate of 61%. The company also noted that median overall survival and median duration of response hadn’t been reached yet, suggesting that median overall survival could surpass 20 months.
Despite the positive results, shares of BCAX stock plummeted 29.12% in pre-market trading. The stock is also down 10.10% year-to-date and has fallen 38.37% over the past 52 weeks. Today’s drop follows a 7.33% rally yesterday, which highlights the volatility clinical-trial pharmaceutical stocks face.
Is BCAX Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Bicara Therapeutics is Moderate Buy, based on four Buy and one Sell ratings over the last three months. With that comes an average BCAX stock price target of $33.25, representing a potential 112.32% upside for the shares.
See more BCAX stock analyst ratings
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue